Immune cell therapy for hard-to-treat autoimmune brain and nerve diseases
Treatments studied
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a neurological autoimmune disease such as NMOSD, myasthenia gravis, MS, autoimmune encephalitis, or CIDP, and it has come back or hasn't responded to standard treatment.
- You are willing to use effective birth control (or abstain) during the study and for 6 months after, if you or your partner can become pregnant. Women must not be pregnant or breastfeeding.
- You are ready to give informed consent and follow the study plan, including attending follow-up visits.
- You have not had cancer in the last 5 years (with a few exceptions like certain early-stage skin or thyroid cancers).
- You do not have serious infections like hepatitis B or C, HIV, or syphilis, and you do not have severe heart problems or serious drug allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.